Nothing Special   »   [go: up one dir, main page]

NO964760L - MSRV-1 virus and pathogenic and / or infectious MSRV-2 agent associated with rheumatoid arthritis - Google Patents

MSRV-1 virus and pathogenic and / or infectious MSRV-2 agent associated with rheumatoid arthritis

Info

Publication number
NO964760L
NO964760L NO964760A NO964760A NO964760L NO 964760 L NO964760 L NO 964760L NO 964760 A NO964760 A NO 964760A NO 964760 A NO964760 A NO 964760A NO 964760 L NO964760 L NO 964760L
Authority
NO
Norway
Prior art keywords
msrv
pathogenic
virus
rheumatoid arthritis
strains
Prior art date
Application number
NO964760A
Other languages
Norwegian (no)
Other versions
NO964760D0 (en
Inventor
Herve Perron
Bernard Mandrand
Francois Mallet
Frederic Bedin
Frederic Beseme
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Publication of NO964760D0 publication Critical patent/NO964760D0/en
Publication of NO964760L publication Critical patent/NO964760L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Oppfinnelsen gjelder anvendelse av et viralt materiale i renset eller iso- lert tilstand, med reverstranskriptase- aktivitet, beslektet med en familie av endogene, retrovirale elementer, og/eller av et patogent og/eller infek- siøst middel i renset eller isolert tilstand som er forskjellig fra det ovenfor nevnte virale materialet, hvor begge er avledet fra en virusstamme med reverstranskriptaseaktivitet valgt blant stammene betegnet POL-2, deponert 22.07.92 hos ECACC under aksesjons- betegnelsen V92072202, henholdsvis MS7- PG, deponert 08.01.93 hos ECACC under aksesjonsbetegnelsen V93010816, og fra variantstammene av disse, som består av virus som omfatter minst ett antigen som gjenkjennes av minst ett antistoff rettet mot minst ett antigen som til- svarer ethvert av virusene fra de oven- for nevnte virusstammer POL-2 og MS7PG, for å fremstille et diagnostisk, profy- laktisk eller terapeutisk preparat for påvisning, forebyggelse eller behand- ling av en infeksjon av dette virale materialet og/eller patogene og/eller infeksiøse middel, forbundet med reumatoid artritt.The invention relates to the use of a viral material in the purified or isolated state, with reverse transcriptase activity, related to a family of endogenous, retroviral elements, and / or of a pathogenic and / or infectious agent in the purified or isolated state which is different from the aforementioned viral material, both of which are derived from a virus strain with reverse transcriptase activity selected from the strains designated POL-2, deposited 22.07.92 with ECACC under accession designation V92072202, respectively MS7-PG, deposited 08.01.93 with ECACC under accession sign V93010816, and from its variant strains, consisting of viruses comprising at least one antigen recognized by at least one antibody directed to at least one antigen corresponding to any of the viruses of the aforementioned virus strains POL-2 and MS7PG, to prepare a diagnostic, prophylactic or therapeutic preparation for the detection, prevention or treatment of an infection of this viral ma the terial and / or pathogenic and / or infectious agent associated with rheumatoid arthritis.

NO964760A 1995-03-09 1996-11-08 MSRV-1 virus and pathogenic and / or infectious MSRV-2 agent associated with rheumatoid arthritis NO964760L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502960A FR2731356B1 (en) 1995-03-09 1995-03-09 MSRV-1 VIRUS AND PATHOGENIC AND / OR INFECTING MSRV-2 AGENT ASSOCIATED WITH RHUMATOID POLYARTHRITIS
PCT/FR1996/000360 WO1996028552A1 (en) 1995-03-09 1996-03-07 Rheumatoid arthritis-related virus msrv-1 and pathogenic and/or infective agent msrv-2

Publications (2)

Publication Number Publication Date
NO964760D0 NO964760D0 (en) 1996-11-08
NO964760L true NO964760L (en) 1996-11-08

Family

ID=9477022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964760A NO964760L (en) 1995-03-09 1996-11-08 MSRV-1 virus and pathogenic and / or infectious MSRV-2 agent associated with rheumatoid arthritis

Country Status (11)

Country Link
EP (1) EP0731168A1 (en)
JP (1) JPH08322579A (en)
AU (1) AU5007396A (en)
BR (1) BR9605926A (en)
CA (1) CA2171242A1 (en)
CZ (1) CZ328796A3 (en)
FR (1) FR2731356B1 (en)
NO (1) NO964760L (en)
NZ (1) NZ303694A (en)
PL (1) PL317200A1 (en)
WO (1) WO1996028552A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737500B1 (en) * 1995-08-03 1997-08-29 Bio Merieux VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR DIAGNOSIS, PROPHYLACTICS AND THERAPEUTICS
ES2331496T3 (en) * 1996-11-26 2010-01-05 Bio Merieux VIRAL MATERIAL AND NUCLEOTID FRAGMENTS ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR DIAGNOSTIC, PROFILACTIC AND THERAPEUTIC PURPOSES.
FR2765588A1 (en) 1997-07-07 1999-01-08 Bio Merieux RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS ESPECIALLY ASSOCIATED WITH MULTIPLE SCLEROSIS AND / OR RHUMATOID POLYARTHRITIS, FOR DIAGNOSIS, PROPHYLACTICS AND THERAPEUTICS
CA2298834C (en) * 1997-07-07 2015-03-10 Bio Merieux Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders
FR2788784A1 (en) * 1999-01-21 2000-07-28 Bio Merieux New nucleic acid from human endogenous retrovirus, useful e.g. for diagnosis of autoimmune disease and complications of pregnancy, contains at least part of the gag gene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689520B1 (en) * 1992-04-03 1996-07-19 Bio Merieux METHOD AND CULTURE MEDIUM FOR OBTAINING CELLS INFECTED WITH A VIRUS ASSOCIATED WITH MULTIPLE SCLEROSIS.
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
AU704440B2 (en) * 1994-02-04 1999-04-22 Bio Merieux MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same

Also Published As

Publication number Publication date
FR2731356B1 (en) 1997-04-30
NO964760D0 (en) 1996-11-08
JPH08322579A (en) 1996-12-10
BR9605926A (en) 1997-09-02
EP0731168A1 (en) 1996-09-11
AU5007396A (en) 1996-10-02
WO1996028552A1 (en) 1996-09-19
NZ303694A (en) 1997-11-24
PL317200A1 (en) 1997-03-17
CZ328796A3 (en) 1997-03-12
CA2171242A1 (en) 1996-09-10
FR2731356A1 (en) 1996-09-13

Similar Documents

Publication Publication Date Title
BHAT et al. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275
NO953925D0 (en) MSRV1 virus and MSRV2 pathogenic and / or infectious agent associated with multiple sclerosis, nucleic acid components and their use
Sethi et al. Phenotypic heterogeneity of cerebrospinal fluid-derived HIV-specific and HLA-restricted cytotoxic T-cell clones
CA2073031A1 (en) Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
DK33190D0 (en) HIV-3 RETROVIRUS AND ITS USE
US5550052A (en) Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells
AU1225088A (en) Peptides having immunological properties 2-hiv-2
WO1996012809A3 (en) Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
FR2731013B1 (en) GROUP O HIV-1, FRAGMENTS OF SAID VIRUSES, AND THEIR APPLICATIONS
DE3855134D1 (en) MONOCLONAL HUMAN ANTIBODIES AGAINST HIV-I
Cotropia et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
DK0494294T3 (en) Bacterial stress proteins
NO964760L (en) MSRV-1 virus and pathogenic and / or infectious MSRV-2 agent associated with rheumatoid arthritis
AU8010791A (en) Hiv monoclonal antibody
DE69941051D1 (en) EXPRESSION AND CHARACTERIZATION OF AN HIV-1 CROP PROTEIN THAT NEUTRALIZES WITH A WIDE REACTIVE
Zandman-Goddard et al. Antiphospholipid antibodies and infections-drugs
McPhee et al. Anomalies in Nef expression within the central nervous system of HIV-1 positive individuals/AIDS patients with or without AIDS dementia complex
JP2008156350A (en) Antigen of transmembrane envelope glycoprotein of human retrovirus hiv type 2 and antigen having immunological similarities with the antigen
Gerenčer et al. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients
CA2109961A1 (en) Peptides for use in induction of t cell activation against hiv-1
SU1768637A1 (en) Strain of human immunodeficient virus 1-type for preparation of diagnostic preparation
Bose et al. Seroepidemiological investigations on human immunodeficiency virus infections in some parts of India
Zhang et al. Human T Lymphotropic Virus Types 1-and II-Specific Antibody-Dependent Cellular Cytotoxicity: Strain Specificity and Epitope Mapping
EP0491888A4 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
ATE128733T1 (en) MONOCLONAL ANTIBODIES AGAINST HIV GP120.